Castle Biosciences
CSTL
CSTL
130 hedge funds and large institutions have $317M invested in Castle Biosciences in 2023 Q2 according to their latest regulatory filings, with 16 funds opening new positions, 70 increasing their positions, 25 reducing their positions, and 34 closing their positions.
New
Increased
Maintained
Reduced
Closed
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more ownership
Funds ownership: →
less funds holding
Funds holding: →
less funds holding in top 10
Funds holding in top 10: →
37% less capital invested
Capital invested by funds: $502M → $317M (-$185M)
51% less call options, than puts
Call options by funds: $325K | Put options by funds: $664K
53% less first-time investments, than exits
New positions opened: 16 | Existing positions closed: 34
Holders
130
Holding in Top 10
2
Calls
$325K
Puts
$664K
Top Buyers
| 1 | +$18.2M | |
| 2 | +$3.54M | |
| 3 | +$2.88M | |
| 4 |
Ameriprise
Minneapolis,
Minnesota
|
+$2.79M |
| 5 |
ICM
Invenomic Capital Management
Boston,
Massachusetts
|
+$2.63M |
Top Sellers
| 1 | -$10.9M | |
| 2 | -$8.3M | |
| 3 | -$6.47M | |
| 4 |
DM
Deerfield Management
New York
|
-$6.18M |
| 5 |
RI
RTW Investments
New York
|
-$5.87M |